Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review

Blossom Christa Maree Stephan, Thais Minett, Emma Pagett, Mario Siervo, Carol Brayne, Ian G McKeith, Blossom Christa Maree Stephan, Thais Minett, Emma Pagett, Mario Siervo, Carol Brayne, Ian G McKeith

Abstract

Objective: To describe how criteria for amnestic Mild Cognitive Impairment (aMCI) have been operationalised in randomised controlled clinical trials (RCTs).

Design: Systematic review.

Information sources: EMBASE, PubMed and PSYCHInfo were searched from their inception to February 2012. Electronic clinical trial registries were also searched (February 2012).

Study selection: RCTs were included where participant selection was made using Petersen et al-defined aMCI. There was no restriction on intervention type or the outcome tested.

Data extraction: For each trial, we extracted information on study design, demographics, exclusion criteria and the operationalisation strategy for the five aMCI diagnostic criteria including: (1) memory complaint, (2) normal general cognitive function, (3) memory impairment, (4) no functional impairment and (5) no dementia.

Results: 223 articles and 278 registered trials were reviewed, of which 22 met inclusion criteria. Various methods were applied for operationalising aMCI criteria resulting in variability in participant selection. Memory complaint and assessment of general cognitive function were the most consistently measured criteria. There was large heterogeneity in the neuropsychological methods used to determine memory impairment. It was not possible to assess the impact of these differences on case selection accuracy for dementia prediction. Further limitations include selective and unclear reporting of how each of the criteria was measured.

Conclusions: The results highlight the urgent need for a standardised approach to map aMCI. Lack of uniformity in clinical diagnosis, however, is not exclusively a problem for MCI but also for other clinical states such as dementia including Alzheimer's disease, Lewy Body, frontotemporal or vascular dementia. Defining a uniform approach to MCI classification, or indeed for any classification concept within the field of dementia, should be a priority if further trials are to be undertaken in the older aged population based on these concepts.

Figures

Figure 1
Figure 1
Petersen criteria for amnestic Mild Cognitive Impairment.
Figure 2
Figure 2
PRISMA (2009) flow diagram of article selection.

References

    1. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003;2:646–53
    1. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280–6
    1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–8
    1. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–92
    1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
    1. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72:1555–61
    1. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Dementias 2005;20:295–302
    1. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007;27:67–70
    1. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–88
    1. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010;5:1–10
    1. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204–15
    1. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024–35
    1. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1538–44
    1. Chen X, Magnotta VA, Duff K, et al. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci 2006;18:178–85
    1. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006;56:159–64
    1. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011;198:351–6
    1. Sherwin BB, Chertkow H, Schipper H, et al. A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging 2011;32:1808–17
    1. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29–38
    1. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010;67:71–9
    1. Scherder EJ, Van Paasschen J, Deijen JB, et al. Physical activity and executive functions in the elderly with mild cognitive impairment. Aging Ment Health 2005;9:272–80
    1. Jean L, Simard M, Wiederkehr S, et al. Efficacy of a cognitive training programme for mild cognitive impairment: results of a randomised controlled study. Neuropsychol Rehabil 2010;20:377–405
    1. Rapp S, Brenes G, Marsh AP. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. Aging Mental Health 2002;6:5–11
    1. Troyer AK, Murphy KJ, Anderson ND, et al. Changing everyday memory behaviour in amnestic mild cognitive impairment: a randomised controlled trial. Neuropsychol Rehabil 2008;18:65–88
    1. Kinsella GJ, Mullaly E, Rand E, et al. Early intervention for mild cognitive impairment: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2009;80:730–6
    1. Buschert VC, Friese U, Teipel SJ, et al. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study. J Alzheimers Dis 2011;25:679–94
    1. Rozzini L, Costardi D, Chilovi V, et al. Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatric Psychiatry 2007;22:356–60
    1. Van Uffelen JGZ, Hopman-Rock M, Chin Aet al. Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688]. BMC Geriatrics 2005;5 doi:
    1. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: the cambridge examination for mental disorders of the elderly. Cambridge: Cambridge University Press, 1988
    1. Gilewski MJ, Zelinski EM. Memory Functioning Questionnaire (MFQ). Psychopharmacol Bull 1988;24:665–70
    1. Strawbridge WJ, Shema SJ, Balfour JL, et al. Antecedents of frailty over three decades in an older cohort. J Gerontol Series B, Psychol Sci Soc Sci 1998;53:S9–16
    1. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
    1. Jurica PJ, Leitten CL, Mattis S. Dementia rating scale-2: professional manual. Lutz: Psychological Assessment Resources, 2001
    1. Mattis S. Dementia rating scale: orofessional manual. Odessa, FL: Psychological Assessment Resources, 1988
    1. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111–17
    1. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–72
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–64
    1. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S22–32
    1. Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310–19
    1. Hebert R, Carrier R, Bilodeau A. The Functional Autonomy Measurement System (SMAF): description and validation of an instrument for the measurement of handicaps. Age Ageing 1988;17:293–302
    1. Morris JC, Mohs RC, Rogers H, et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641–52
    1. Kempen GI, Miedema I, Ormel J, et al. The assessment of disability with the Groningen activity restriction scale. Conceptual framework and psychometric properties. Soc Sci Med 1996;43:1601–10
    1. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–86
    1. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20–30
    1. Wedderburn C, Wear H, Brown J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008;79:500–3
    1. American Psychiatric Association Diagnostic and statistical manual of mental disorders (Third Edition, revised) (DSM-III-R). Washington, DC: APA, 1987
    1. American Psychiatric Association Diagnostic and statistical manual of mental disorders (Fourth Edition) (Text Revision: DMS-IV-TR). Arlington, VA: American Psychiatric Publishing Inc, 2000
    1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44
    1. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–60
    1. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–9
    1. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatric Psychiatry 2012;26:592–600
    1. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004;16:275–93
    1. EuroQol Group EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208
    1. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 1995;52:612–19
    1. Duara R, Loewenstein DA, Greig MT, et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatric Psychiatry 2011;19:951–60
    1. Stephan BC, Matthews FE, Khaw KT, et al. Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimer's Res Ther 2009;1:4.
    1. Stephan BC, Matthews FE, McKeith IG, et al. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc 2007;55:1534–40
    1. Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 2008;56:1424–33
    1. Erkinjuntti T, Ostbye T, Steenhuis R, et al. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667–74
    1. Wancata J, Borjesson-Hanson A, Ostling S, et al. Diagnostic criteria influence dementia prevalence. Am J Geriatric Psychiatry 2007;15:1034–45
    1. Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009;24:902–15
    1. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 2009;119:252–65
    1. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15–21
    1. Panza F, Capurso C, D'Introno A, et al. Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. Neurobiol Aging 2007;28:1631–2
    1. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201–9
    1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118–27
    1. Whitehair DC, Sherzai A, Emond J, et al. Influence of apolipoprotein e (epsilon)4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's Dementia 2010;6:412–19
    1. Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–28
    1. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262–70
    1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–92
    1. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–6
    1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270–9
    1. Matthews FE, Stephan BC, Bond J, et al. Operationalization of mild cognitive impairment: a graphical approach. PLoS Med 2007;4:1615–19

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi